98%
921
2 minutes
20
Background: Venom immunotherapy (VIT) is an effective treatment in the patients at high risk of anaphylaxis or life-threatening systemic reactions due to Hymenoptera venom allergy. But, systemic and large local reactions can be observed, especially during the build-up phase of VIT. We evaluated the safety of conventional and ultra-rush build-up protocols.
Materials And Methods: Two protocols in 71 patients (39 conventional and 32 ultra-rush protocols) with honeybee and wasp venom allergy were evaluated retrospectively. Patients were diagnosed and selected for VIT according to the criteria established by the European Academy of Allergy and Clinical Immunology. The severity of systemic reactions was evaluated according to the criteria of Mueller.
Results: Build-up phases were tolerated in 66.2% ( = 47) without any reaction. Allergic adverse reactions were observed in 33.8% ( = 24): large local reactions 22.5% ( = 16) and systemic reactions 11.3% ( = 8). There was no significant difference in the number of adverse reactions comparing patients receiving conventional and ultra-rush protocol. In addition, no association was found between allergic adverse reactions and the following factors: sex, previous systemic sting reactions, honeybee and wasp venom extract.
Conclusion: We found that both protocols were tolerated in patients with honeybee and wasp venom allergy. Ultra-rush protocol will be preferred for patients and clinicians because of its advantages in terms of time and costs.KEY MESSAGESVIT is the only curative treatment method that reduces the risk of severe reactions after a bee sting and improves the quality of life in patients with Hymenoptera venom allergy.Ultra-rush VIT protocol has advantages such as few injection and time savings.Both ultra-rush and conventional VIT are safe treatments to prevent potentially life-threatening reactions in patients with honeybee and wasp venom allergy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487973 | PMC |
http://dx.doi.org/10.1080/07853890.2022.2112969 | DOI Listing |
Acta Pharmacol Sin
September 2025
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
The anti-HER2 antibody‒drug conjugate (ADC) DS-8201 presents new hope for patients with advanced HER2-positive tumors. Its clinical application, however, is hindered by serious adverse reactions and reduced efficacy following long-term treatment. In this study, we investigated the factors influencing the sensitivity of DS-8201 and developed effective combination regimens to optimize its therapeutic efficacy.
View Article and Find Full Text PDFRen Fail
December 2025
Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China.
This study aimed to develop a predictive model and construct a graded nomogram to estimate the risk of severe acute kidney injury (AKI) in patients without preexisting kidney dysfunction undergoing liver transplantation (LT). Patients undergoing LT between January 2022 and June 2023 were prospectively screened. Severe AKI was defined as Kidney Disease: Improving Global Outcomes stage 3.
View Article and Find Full Text PDFAm J Geriatr Psychiatry
August 2025
Mood Disorder and Psychopharmacology Unit (RS, JKT, CED, RSM), University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronnto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, ON, Canada. Electronic address: roger.mcintyre@
Ketamine has emerged as a promising treatment for major depression, though its efficacy and safety remain incompletely characterized in older adults. This systematic review synthesizes current evidence for ketamine in geriatric depression. A search of PubMed, EMBASE, and PsycINFO was conducted.
View Article and Find Full Text PDFInd Health
September 2025
Ministry of Employment and Labor, Republic of Korea.
Research on worker exposure to volatile organic compounds (VOCs) during asphalt paving operations remains significantly limited, and regulatory frameworks governing such exposures are also insufficient. Previous studies have primarily focused on a limited number of major VOCs. However, this study employs high-resolution, high-performance Proton Transfer Reaction Time-of-Flight Mass Spectrometry (PTR-ToF-MS) to comprehensively evaluate exposure levels to 25 different VOCs.
View Article and Find Full Text PDFJ Safety Res
September 2025
School of Health and Biomedical Sciences, RMIT University, Australia; Institute for Breathing and Sleep, Austin Health, Heidelberg, Australia.
Introduction: Drowsiness is a significant cause of crashes in the various transport industries, including automotive, aviation, and rail. Our previous study investigated the differential induction of drowsiness in drivers caused by specific whole-body vibration (WBV) frequency ranges, with an amplitude of 0.2 m/s r.
View Article and Find Full Text PDF